Kamada Announces Successful Interim Results of Phase II Deposition Study with Aerosolized AATNESS ZIONA, Israel--(BUSINESS WIRE)--June 9, 2008 - Kamada, a bio-pharmaceutical company (www.kamada.com) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today of successful interim results in a Phase II deposition study with its Aerosolized AAT product delivered by PARI's optimized eFlow(R) electronic nebulizer to treat Alpha-1 Deficiency and other respiratory diseases.
According to David Tsur, CEO Kamada, "This significant milestone demonstrates the high potential of the company's Aerosolized AAT product currently undergoing advanced clinical trials for several indications. These interim trial results meet our expectations and support the clinical plan."
According to Pnina Strauss, Clinical Trials & IP Manager, "This next generation product, Aerosolized AAT, holds numerous advantages over the currently used AAT for intravenous administration. Among these advantages are greater patient convenience, reduced treatment costs, larger treatment population and additional potential indications, all pending successful completion of the company's clinical development plan."
Kamada's aerosolized AAT drug was designated by both the US-FDA and the European Agency for the Evaluation of Medicinal Products (EMEA) as an Orphan Drug for Congenital Emphysema and CF as well as for Bronchiectasis by the US-FDA. This important attribute will allow the company research funds benefits, waiver of user fees and free scientific advice by the regulatory authorities. Furthermore, if Kamada is the first company to successfully complete clinical trials and receive marketing approval in the US or the EU, the company shall gain exclusive marketing rights for the duration of seven years in the US, and for 10 or 12 years in Europe.
About PARI's eFlow(R)
eFlow(R), an electronic, portable nebulizer, enables extremely efficient aerosolization of liquid medications via a vibrating, perforated membrane. Compared to other nebulizer systems, eFlow(R) can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, PARI's eFlow(R) helps reduce the burden of taking daily inhaled treatments.
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as the eFlow(R).
Kamada is a public biopharmaceutical company (TASE:KMDA) developing, producing and marketing a line of specialty life-saving therapeutics using its proprietary chromatographic purification technologies. Licensed and marketed in more than 15 countries, several of these specialty therapeutics hold registered and pending patents and are currently in advanced clinical trials.
For additional information, please visit www.kamada.com
Sivan Shatil, Marketing Communications
Posted: June 2008